

## AMENDMENTS TO THE CLAIMS

1-2. (canceled)

3. (previously presented) An isolated antibody that selectively binds to a polypeptide, wherein the amino acid sequence of said polypeptide consists of SEQ ID NO:2.

4-15. (canceled)

16. (previously presented) The antibody of claim 3, wherein the antibody is a monoclonal antibody.

17. (canceled)

18. (currently amended) ~~The antibody of claim 3,~~ A labeled antibody that selectively binds to a polypeptide, wherein the amino acid sequence of said polypeptide consists of SEQ ID NO:2, and wherein the antibody is coupled to a detectable substance.

19. (canceled)

20. (currently amended) ~~The antibody of claim 16,~~ A labeled antibody that selectively binds to a polypeptide, wherein the amino acid sequence of said polypeptide consists of SEQ ID NO:2, and wherein the antibody is a monoclonal antibody, and further wherein the antibody is coupled to a detectable substance.

21. (canceled)

22. (previously presented) A composition comprising the antibody of claim 3 and a pharmaceutically acceptable carrier.

23. (canceled)

24. (previously presented) A composition comprising the antibody of claim 16 and a pharmaceutically acceptable carrier.

25. (previously presented) A composition comprising the antibody of claim 17 and a pharmaceutically acceptable carrier.

26. (previously presented) An isolated antibody fragment that selectively binds to a polypeptide, wherein the amino acid sequence of said polypeptide consists of SEQ ID NO:2, and wherein the antibody fragment comprises a fragment selected from the group consisting of:

- a) an Fab fragment;
- b) an F(ab')<sub>2</sub> fragment; and
- c) an Fv fragment.

27-29. (canceled)